Kyowa Kirin, a global specialty pharmaceutical company, is implementing the AI platform Benchling at its Tokyo and Fuji Research Parks to enhance research and development. Supported by Cognizant, Benchling will automate workflows, integrate data management, and enable AI-driven experiment planning and molecular design. This integration aims to accelerate drug discovery cycles, improve data accuracy, and boost researcher productivity, helping Kyowa Kirin address complex medical challenges and expand its innovative pipeline. The collaboration also focuses on cost efficiency and flexible expense management for sustainable growth.
Cognizant announced it will participate in two upcoming investor conferences in September 2026: Citi's Global TMT Conference on September 8 and Truist Securities Technology Symposium on September 15. The CFO and CEO will present, sharing insights on ...
Cognizant and CrowdStrike have expanded their partnership to introduce Cognizant Cybersecurity for Operational Technology, powered by CrowdStrike Falcon for XIoT. This service offers unified security visibility and protection across operational techn...
